Proactive Investors - Run By Investors For Investors

Constellation Pharmaceuticals presents poster on studies involving drug therapy to treat bladder cancer

Patricia Keller, senior scientist at Constellation, made the poster presentation at the American Association for Cancer Research in Denver
bladder
The poster discusses results of Constellation’s work with its second-generation EZH2 inhibitor CPI-0209 in bladder cancer models

Constellation Pharmaceuticals Inc (NASDAQ:CNST) fell into the red Monday on the same day the company presented a poster on studies involving the company’s drug therapy to treat bladder cancer.

The Cambridge, Massachusetts-based company’s stock recently traded at $8.99 a share, down 15.4% on higher-than-average volume.

Patricia Keller, senior scientist at Constellation, made the poster presentation titled "targeting epigentic dysregulation in bladder cancer through inhibition of EZH2" at the Bladder Cancer: Transforming the Field meeting of the American Association for Cancer Research in Denver.

The poster discusses results of Constellation’s work with its second-generation EZH2 inhibitor CPI-0209 in bladder cancer models, exploring whether ARIDA mutation status affected responsiveness to CPI-0209 treatment, according to a statement. 

ARID1A, a protein that is a key component of the SWI/SNF chromatin remodeling complex, is mutated in about 25% of muscle-invasive bladder cancers, the company said.

Constellation used CPI-0209 in long-term phenotypic growth assays in a panel of 21 bladder cancer cell lines, demonstrating preferential treatment sensitivity that correlated with increased cell death in cell lines harboring ARID1A mutations. Transcriptional profiling after CPI-0209 treatment showed widespread activation of EZH2 target gene expression, the company said. 

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

View full CNST profile View Profile

Related Articles

test tubes
May 07 2019
Here we take a closer look at Arix Biosciences PLC (LON:ARIX), a listed venture capital company that doesn’t appear to be receiving the recognition it deserves
cancer scan
January 03 2019
The company, which owns a piece of software which predicts the effects of drugs on cancers, has recently extended a lucrative agreement with German firm Merck Serono while it has also signed a strategic collaboration with the Medicines Discovery Catapult
CBD oil
November 16 2018
The company’s technology creates nano-scale emulsion mixtures that allow fluids to mix that normally don’t mix, such as CBD oil and water

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use